Hypophysitis Secondary to Cytotoxic T-Lymphocyte–Associated Protein 4 Blockade: Insights into Pathogenesis from an Autopsy Series

American Journal of Pathology

Volumn 186, Issue 12, 2016, Pages 3225-3235

  Caturegli, Patrizio ^a   Di Dalmazi, Giulia ^a,b   Lombardi, Martina ^c   Grosso, Federica ^c   Larman, H Benjamin ^a   Larman, Tatianna ^a   Taverna, Giacomo ^d   Cosottini, Mirco ^e   Lupi, Isabella ^e  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHIETI   (Italy)

^c Divisione di Ematologia   (Italy)

^d Saint Spirit Hospital   (Italy)

^e UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLOCKING ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN G; CTLA4 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; AUTOPSY; CANCER PATIENT; CELL INFILTRATION; CLINICAL ARTICLE; CYTOTOXIC T LYMPHOCYTE; ENDOCRINE CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERSENSITIVITY; HYPOPHYSIS; HYPOPHYSIS ADENOMA; HYPOPHYSIS FUNCTION; HYPOPHYSITIS; IMMUNITY; LYMPHOCYTIC INFILTRATION; MALE; MIDDLE AGED; PATHOGENESIS; PRIORITY JOURNAL; ANTAGONISTS AND INHIBITORS; IMMUNOLOGY; METABOLISM; PATHOLOGY; PITUITARY NEOPLASMS;

ADULT; AGED; ANTIBODIES, BLOCKING; ANTIBODIES, MONOCLONAL; AUTOPSY; CTLA-4 ANTIGEN; FEMALE; HUMANS; HYPOPHYSITIS; MALE; MIDDLE AGED; PITUITARY GLAND; PITUITARY NEOPLASMS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84995906230     PISSN: 00029440     EISSN: 15252191     Source Type: Journal    
DOI: 10.1016/j.ajpath.2016.08.020     Document Type: Article

References (33)

1. 1 Leporati, P., Landek-Salgado, M.A., Lupi, I., Chiovato, L., Caturegli, P., IgG4-related hypophysitis: a new addition to the hypophysitis spectrum. J Clin Endocrinol Metab 96 (2011), 1971–1980.
2. 2 Caturegli, P., Iwama, S., From Japan with love: another tessera in the hypophysitis mosaic. J Clin Endocrinol Metab 98 (2013), 1865–1868.
3. 3 Caturegli, P., Newschaffer, C., Olivi, A., Pomper, M.G., Burger, P.C., Rose, N.R., Autoimmune hypophysitis. Endocr Rev 26 (2005), 599–614.
4. 4 Deodhare, S.S., Bilbao, J.M., Kovacs, K., Horvath, E., Nomikos, P., Buchfelder, M., Reschke, K., Lehnert, H., Xanthomatous hypophysitis: a novel entity of obscure etiology. Endocr Pathol 10 (1999), 237–241.
5. 5 van der Vliet, H.J., Perenboom, R.M., Multiple pseudotumors in IgG4-associated multifocal systemic fibrosis. Ann Intern Med 141 (2004), 896–897.
6. 6 Ahmed, S.R., Aiello, D.P., Page, R., Hopper, K., Towfighi, J., Santen, R.J., Necrotizing infundibulo-hypophysitis: a unique syndrome of diabetes insipidus and hypopituitarism. J Clin Endocrinol Metab 76 (1993), 1499–1504.
7. 7 Phan, G.Q., Yang, J.C., Sherry, R.M., Hwu, P., Topalian, S.L., Schwartzentruber, D.J., Restifo, N.P., Haworth, L.R., Seipp, C.A., Freezer, L.J., Morton, K.E., Mavroukakis, S.A., Duray, P.H., Steinberg, S.M., Allison, J.P., Davis, T.A., Rosenberg, S.A., Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 100 (2003), 8372–8377.
8. 8 Gutenberg, A., Landek-Salgado, M.A., Tzou, S.C., Lupi, I., Geis, A., Kimura, H., Caturegli, P., Autoimmune hypophysitis: expanding the differential diagnosis to CTLA-4 blockade. Expert Rev Endocrinol Metab 4 (2009), 681–698.
9. 9 Albarel, F., Gaudy, C., Castinetti, F., Carre, T., Morange, I., Conte-Devolx, B., Grob, J.J., Brue, T., Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. Eur J Endocrinol 172 (2014), 195–204.
10. 10 Faje, A.T., Sullivan, R., Lawrence, D., Tritos, N.A., Fadden, R., Klibanski, A., Nachtigall, L., Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. J Clin Endocrinol Metab 99 (2014), 4078–4085.
11. 11 Min, L., Hodi, F.S., Giobbie-Hurder, A., Ott, P.A., Luke, J.J., Donahue, H., Davis, M., Carroll, R.S., Kaiser, U.B., Systemic high dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clin Cancer Res 21 (2014), 749–755.
12. 12 Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., McDermott, D.F., Powderly, J.D., Carvajal, R.D., Sosman, J.A., Atkins, M.B., Leming, P.D., Spigel, D.R., Antonia, S.J., Horn, L., Drake, C.G., Pardoll, D.M., Chen, L., Sharfman, W.H., Anders, R.A., Taube, J.M., McMiller, T.L., Xu, H., Korman, A.J., Jure-Kunkel, M., Agrawal, S., McDonald, D., Kollia, G.D., Gupta, A., Wigginton, J.M., Sznol, M., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366 (2012), 2443–2454.
13. 13 Brahmer, J.R., Tykodi, S.S., Chow, L.Q., Hwu, W.J., Topalian, S.L., Hwu, P., Drake, C.G., Camacho, L.H., Kauh, J., Odunsi, K., Pitot, H.C., Hamid, O., Bhatia, S., Martins, R., Eaton, K., Chen, S., Salay, T.M., Alaparthy, S., Grosso, J.F., Korman, A.J., Parker, S.M., Agrawal, S., Goldberg, S.M., Pardoll, D.M., Gupta, A., Wigginton, J.M., Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366 (2012), 2455–2465.
14. 14 Abdel-Rahman, O., ElHalawani, H., Fouad, M., Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. Future Oncol 12 (2016), 413–425.
15. 15 Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M.E., Schaeverbeke, T., Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med, 13, 2015, 211.
16. 16 Wehler, E., Zhao, Z., Pinar Bilir, S., Munakata, J., Barber, B., Economic burden of toxicities associated with treating metastatic melanoma in eight countries. Eur J Health Econ, 2015 [Epub ahead of print] doi: 10.1007/s10198-015-0757-y.
17. 17 Barzey, V., Atkins, M.B., Garrison, L.P., Asukai, Y., Kotapati, S., Penrod, J.R., Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis. J Med Econ 16 (2013), 202–212.
18. 18 Tsunoda, A., Okuda, O., Sato, K., MR height of the pituitary gland as a function of age and sex: especially physiological hypertrophy in adolescence and in climacterium. AJNR Am J Neuroradiol 18 (1997), 551–554.
19. 19 Iwama, S., De Remigis, A., Callahan, M.K., Slovin, S.F., Wolchok, J.D., Caturegli, P., Pituitary expression of ctla-4 mediates hypophysitis secondary to administration of ctla-4 blocking antibody. Sci Transl Med, 6, 2014, 230ra45.
20. 20 Pollock, A.J., Seibert, T.S., Salvatori, C., Caturegli, P., Allen, D.B., Pituitary antibodies in an adolescent with secondary adrenal insufficiency and Turner syndrome. Hormone Res Paediatr, 2016 [Epub ahead of print] doi: 10.1159/000446912.
21. 21 Zheng, G., Chaux, A., Sharma, R., Netto, G., Caturegli, P., LMP2, a novel immunohistochemical marker to distinguish renal oncocytoma from the eosinophilic variant of chromophobe renal cell carcinoma. Exp Mol Pathol 94 (2013), 29–32.
22. 22 Uzzaman, A., Cho, S.H., Classification of hypersensitivity reactions. Allergy Asthma Proc 33:Suppl 1 (2012), S96–S99.
23. 23 Faje, A., Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 19 (2015), 82–92.
24. 24 Joshi, M.N., Whitelaw, B.C., Palomar, M.T., Wu, Y., Carroll, P.V., Immune checkpoint inhibitor related hypophysitis and endocrine dysfunction: clinical review. Clin Endocrinol (Oxf) 85 (2016), 331–339.
25. 25 Michot, J.M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., Massard, C., Fuerea, A., Ribrag, V., Gazzah, A., Armand, J.P., Amellal, N., Angevin, E., Noel, N., Boutros, C., Mateus, C., Robert, C., Soria, J.C., Marabelle, A., Lambotte, O., Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54 (2016), 139–148.
26. 26 Crowne, E., Gleeson, H., Benghiat, H., Sanghera, P., Toogood, A., Effect of cancer treatment on hypothalamic-pituitary function. Lancet Diabetes Endocrinol 3 (2015), 568–576.
27. 27 Tiu, C., Pezaro, C., Davis, I.D., Grossmann, M., Parente, P., Early recognition of ipilimumab-related autoimmune hypophysitis in patients with metastatic melanoma: case studies and recommendations for management. Asia Pac J Clin Oncol 11 (2015), 190–194.
28. 28 Mahzari, M., Liu, D., Arnaout, A., Lochnan, H., Immune checkpoint inhibitor therapy associated hypophysitis. Clin Med Insights Endocrinol Diabetes 8 (2015), 21–28.
29. 29 Tai, X., Van Laethem, F., Pobezinsky, L., Guinter, T., Sharrow, S.O., Adams, A., Granger, L., Kruhlak, M., Lindsten, T., Thompson, C.B., Feigenbaum, L., Singer, A., Basis of CTLA-4 function in regulatory and conventional CD4(+) T cells. Blood 119 (2012), 5155–5163.
30. 30 Szczerba, B.M., Kaplonek, P., Wolska, N., Podsiadlowska, A., Rybakowska, P.D., Dey, P., Rasmussen, A., Grundahl, K., Hefner, K.S., Stone, D.U., Young, S., Lewis, D.M., Radfar, L., Scofield, R.H., Sivils, K.L., Bagavant, H., Deshmukh, U.S., Interaction between innate immunity and Ro52-induced antibody causes Sjogren's syndrome-like disorder in mice. Ann Rheum Dis 75 (2016), 617–622.
31. 31 Gough, S.C., Walker, L.S., Sansom, D.M., CTLA4 gene polymorphism and autoimmunity. Immunol Rev 204 (2005), 102–115.
32. 32 Sanderson, K., Scotland, R., Lee, P., Liu, D., Groshen, S., Snively, J., Sian, S., Nichol, G., Davis, T., Keler, T., Yellin, M., Weber, J., Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol 23 (2005), 741–750.
33. 33 Breunis, W.B., Tarazona-Santos, E., Chen, R., Kiley, M., Rosenberg, S.A., Chanock, S.J., Influence of cytotoxic T lymphocyte-associated antigen 4 (CTLA4) common polymorphisms on outcome in treatment of melanoma patients with CTLA-4 blockade. J Immunother 31 (2008), 586–590.